March 31st 2025
Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers
View More
Shortened Adjuvant Treatment Duration Reduced Toxicity Without Impacting Efficacy in Colon Cancer
November 9th 2022For patients with colon cancer, 3-month treatment with mFOLFOX6 or CAPOX improved safety outcomes without affecting efficacy vs 6-month treatment, according to data from the phase 3 ACHIEVE trial.
Trifluridine/Tipiracil Plus Bevacizumab Reaches Survival Endpoint in mCRC
October 11th 2022Data from the phase 3 SUNLIGHT study highlighted the increased survival benefit of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone for the treatment of metastatic colorectal cancer.
FDA Grants Priority Review to Tucatinib Plus Trastuzumab for Previously Treated HER2+ Metastatic CRC
September 20th 2022Patients with previously treated, metastatic, HER2-positive colorectal cancer may benefit from treatment with tucatinib and trastuzumab, which was granted priority review by the FDA.
Christine Parseghian, MD, on Promise of EGFR Rechallenge Therapy in Certain Patients With mCRC
September 7th 2022At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.
Neoadjuvant Chemo May Reduce Necessity of Invasive Surgeries in Early-Stage Rectal Cancer
September 1st 2022Three months of neoadjuvant chemotherapy may downstage early-stage rectal cancer and thereby reduce the need for total mesorectal excisions (TMEs), resulting in higher rates of organ preservation.
TP53 Gain-of-Function Status Linked With Outcomes Based on Sidedness in Metastatic CRC
August 18th 2022Investigators found that patients with non–gain-of-function TP53-mutant right-sided metastatic colorectal cancer and gain-of-function TP53-mutant left-sided tumors had poorer survival vs their counterparts.